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 Here, mathematical modelling shows that hospital infection control (HIC) interventions can 
preferentially reduce hospital-adapted strains over community-adapted strains within and 
outside hospitals, questioning our conclusion that restrictions in fluoroquinolone use were 
responsible for most of the decline in C. difficile infection (CDI).1  ?ůůŵŽĚĞůƐĂƌĞǁƌŽŶŐ ?ďƵƚ
ƐŽŵĞĂƌĞƵƐĞĨƵů ? ?'ĞŽƌŐĞŽǆ ? ?The key is not whether a model can reproduce findings from 
an empirical study, but whether its underpinning assumptions are sufficiently plausible. 
Unfortunately, several features are implausible in this model, which seems more 
appropriate to MRSA. 
 
Firstly fluoroquinolone-resistant strains are assumed to be hospital-adapted, i.e. transmit 
more efficiently in hospital, and, crucially, fluoroquinolone-susceptible strains are assumed 
community-adapted. The former is possible, since C. difficile transmission may be 
promoted, at least partly, by resistance itself. But why the latter should hold is unclear, 
particularly as most fluoroquinolone use in our study was in the community. Additionally, if 
resistance itself confers hospital-adaptation, reducing fluoroquinolone use would be 
expected to reduce hospital-adaptation; this is not considered in the model. 
 
The second assumption is competition between fluoroquinolone-resistant and 
fluoroquinolone-susceptible C. difficile, i.e. infection by one precludes the other. This is 
required for the incidence of susceptible strains to remain unchanged despite HIC 
interventions. However, as acknowledged, this is a simplification; rates of CDI with multiple 
genotypes are ~7%.2 Third ?ƚŚĞŵŽĚĞů ?ƐƉĂƌĂŵĞƚĞƌƐproduce implausibly high C. difficile 
prevalence (>20%/10% in hospital/community), contradicting empirical observations 
(ƚǇƉŝĐĂůůǇA? ? ?A?ĂŶĚ ? ?A? ?ƌĞƐƉĞĐƚŝǀĞůǇ).3 Both exaggerate competition in the model. 
 
Fourth, the model assumes that bacteria are transmitted in hospitals exclusively via 
healthcare workers (HCW). Whilst patient-to-patient transmission is modelled in the 
community, it is not within hospitals, and no contribution from the environment or other 
reservoirs is allowed. This clearly substantially amplifies the effect of any HCW intervention.  
 
Fifth, the model considers only asymptomatic colonisation, which is never treated, so the 
mean 200-day carriage duration of resistant-bacteria, regardless of location, may be 
reasonable. However, for unclear reasons, susceptible-bacteria are assumed to be lost 3.3-
fold faster in hospital than resistant-bacteria, but at the same rate in the community. 
Infections are not directly modelled, despite CDI symptoms being a key determinant of 
transmission (in contrast with MRSA).4 Instead, the model assumes 1 in 10 colonisations 
result in symptomatic infections; these would be treated, and the vast majority of 
fluoroquinolone-susceptible and fluoroquinolone-resistant isolates are equally susceptible 
to first-line CDI therapy (metronidazole/vancomycin), giving no advantage to either.  
  
The authors raise an intriguing question that merits careful consideration across a range of 
healthcare-associated infections. We would welcome the opportunity to work with them to 
explore the performance of their model under realistic assumptions for C. difficile; 
particularly to explore why stewardship interventions may achieve CDI control despite prior 
multi-factorial HIC measures not doing so,5 and why reductions in CDI have not occurred in 
North America, despite similar HIC interventions, but without fluoroquinolone restriction.  
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